About This Desk

What Peptide Med Group is

Peptide Med Group tracks four research peptides — ipamorelin, NAD+, thymosin alpha-1, and tirzepatide — organized around one question: how much clinical-trial evidence actually exists for each, and what did it find. Tirzepatide leads this desk because its trial record is the deepest of the four: multiple completed Phase 3 programs and FDA approval. The other three sit at different points on the same scale, from thymosin alpha-1's real but null Phase 3 sepsis trial, to NAD+'s solid smaller trials on biomarkers, to ipamorelin's single negative human study.

The organizing discipline is simple: state what a specific trial tested, in whom, and what it found. Don't round a Phase 2 signal up to a clinical fact. Don't let a compound's marketing outrun its evidence. Where a trial failed its primary endpoint, this desk says so — that's data too.

How it is compiled

Every factual claim on this site ties to a numbered citation, collected on the references page — peer-reviewed journal articles, clinical-trial publications, and clinical-reference chapters, each with a DOI or PubMed link. Where a claim comes from a review rather than a primary trial, the text says so.

Findings are reported at the strength they were actually studied at. A rat study is reported as a rat study. A Phase 2 trial that missed its endpoint is reported as a trial that missed its endpoint, not softened into a maybe. Where a compound's real-world community reports exist, they're labeled as anecdotal and kept separate from the cited clinical record — the two are never blended into one claim.

The four compound pages cross-reference each other and a shared comparison page, so a reader can follow one theme — trial depth, mechanism, safety signal — across all four.

What it is not

Peptide Med Group is not a pharmacy, a clinic, or a vendor. It doesn't sell, source, or broker any compound, and it has no referral relationship with any manufacturer or research-chemical supplier. It doesn't diagnose, prescribe, or recommend a dose for any person.

A licensed prescriber weighs a patient's case before issuing any tirzepatide prescription; a request alone settles nothing. Thymosin alpha-1 is approved abroad, not in the US; here, a licensed U.S. clinician can consider a compounded prescription after evaluating the individual. NAD+ supplements are still sold, while the injectable form calls for a clinician's prescription decision. Each compounded preparation has no FDA approval. State rules and the treatment in question set further limits on U.S. prescription care. Ipamorelin has no approval anywhere. Readers seeking clinical guidance should consult a licensed provider in their own jurisdiction. Editorial correspondence — citation corrections, new trial results — goes through the contact page.